Non-Invasive Preeclampsia Screening and Biobank
ConditionPreeclampsia (PE)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorSequenom, Inc.
About this trial
Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.
Eligibility criteria
Qualifiers
Subject is female and 18 years of age and older;
Subject provides a signed and dated informed consent;
Subject is pregnant with a singleton pregnancy at ≥11.0 - ≤14.0 weeks' gestation;
Subject agrees to provide the Sponsor access to any prenatal and postnatal screening or diagnostic test results and supporting data;
Disqualifiers
Subject is unlikely to return for second and third trimester testing;
Subject is unlikely to have pregnancy outcome data available;
Previous sample donation under this protocol with the same pregnancy;
Subject is participating in a blinded aspirin study or taking unknown doses of aspirin.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
6,550 Participants
are grouped into 1 trial groupLocations
21Arizona
Valley Perinatal85304, Glendale United States
Delaware
Delaware Center for Maternal and Fetal Medicine19718, Newark United States
Florida
D&H National Research Centers33155, Miami United States
Louisiana
Southern Clinical Research Associates70001, Metairie United States
Sponsors and collaborators
Sequenom, Inc.
Lead sponsor
Rutgers Robert Wood Johnson Medical School
Collaborator
Laboratory Corporation of America
Collaborator
Source ClinicalTrials.gov